Significant elevation of aqueous endothelin-1 in central retinal vein occlusion.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
02
2021
accepted:
17
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
11
11
2021
Statut:
epublish
Résumé
To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group. A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month. At baseline, the mean aqueous ET-1 level was 12.7±3.6 pg/mL in the CRVO group, 8.0±2.3 pg/mL in the BRVO group, and 2.0±0.9 pg/mL in the control group (P<0.001). After IVB, the mean aqueous level of ET-1 was 3.4±1.9 pg/mL (0.5-6.9 pg/mL) in the CRVO group and 1.8±1.0 pg/mL (0.3-3.2 pg/mL) in the BRVO group (P = 0.008). The mean aqueous ET-1 level was significantly reduced in both the patients with CRVO and those with BRVO (P<0.001). The mean aqueous humor ET-1 level was significant higher in the patients with CRVO than those with BRVO and in the control group. After IVB, the mean level was significantly reduced in both the patients with CRVO and those with BRVO.
Identifiants
pubmed: 34077461
doi: 10.1371/journal.pone.0252530
pii: PONE-D-21-06459
pmc: PMC8171894
doi:
Substances chimiques
Endothelin-1
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0252530Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
EPMA J. 2016 Aug 24;7(1):18
pubmed: 27559424
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S455-8
pubmed: 15838347
Arch Ophthalmol. 1986 Jan;104(1):34-41
pubmed: 2417579
Retina. 1981;1(1):27-55
pubmed: 15633406
Trends Pharmacol Sci. 1989 Sep;10(9):374-8
pubmed: 2690429
J Glaucoma. 2013 Feb;22(2):104-9
pubmed: 21946550
Eur J Pharmacol. 2005 Jul 11;517(3):232-9
pubmed: 15975571
Ophthalmology. 2004 Aug;111(8):1489-94
pubmed: 15288976
Nature. 1988 Mar 31;332(6163):411-5
pubmed: 2451132
Lancet. 1989 Jul 1;2(8653):53-4
pubmed: 2567834
Invest Ophthalmol Vis Sci. 2011 May 16;52(6):3215-20
pubmed: 21345988
Ophthalmol Retina. 2017 Sep - Oct;1(5):404-412
pubmed: 31047570
Graefes Arch Clin Exp Ophthalmol. 1993 Aug;231(8):476-81
pubmed: 8224948
Biochem Biophys Res Commun. 2004 Jun 4;318(3):642-8
pubmed: 15144886
Hypertension. 1998 Jul;32(1):89-95
pubmed: 9674643
Curr Eye Res. 1998 May;17(5):541-5
pubmed: 9617550
J Glaucoma. 2002 Apr;11(2):105-9
pubmed: 11912357
Surv Ophthalmol. 2007 Nov;52 Suppl 2:S115-21
pubmed: 17998035
Exp Biol Med (Maywood). 2006 Jun;231(6):1085-9
pubmed: 16741054
N Engl J Med. 1990 Jan 18;322(3):205
pubmed: 2403657
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S376-9
pubmed: 15838324
Am J Ophthalmol. 1994 Jan 15;117(1):72-80
pubmed: 8291596
Exp Eye Res. 2018 Nov;176:207-209
pubmed: 30025919
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):412-9
pubmed: 26848880
Circulation. 1991 Oct;84(4):1457-68
pubmed: 1655302
Br J Ophthalmol. 1998 May;82(5):498-503
pubmed: 9713055
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):272-7
pubmed: 16384973
Arch Ophthalmol. 2008 Apr;126(4):513-8
pubmed: 18413521